Natera (NASDAQ:NTRA) Price Target Increased to $150.00 by Analysts at Leerink Partners

Natera (NASDAQ:NTRA) had its target price lifted by equities research analysts at Leerink Partners from $140.00 to $150.00 in a research report issued on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the medical research company’s stock. Leerink Partners’ price target indicates a potential upside of 19.53% from the stock’s current price.

Other analysts have also recently issued research reports about the company. Stephens reissued an “overweight” rating and set a $125.00 price objective on shares of Natera in a research report on Friday, August 9th. Morgan Stanley boosted their price target on Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. Robert W. Baird raised their price objective on shares of Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. The Goldman Sachs Group boosted their target price on shares of Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, UBS Group cut their price target on shares of Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, Natera has a consensus rating of “Moderate Buy” and a consensus price target of $124.44.

Natera Stock Down 1.0 %

NASDAQ:NTRA traded down $1.28 on Thursday, hitting $125.49. 97,549 shares of the company’s stock traded hands, compared to its average volume of 1,338,109. The company has a market cap of $15.41 billion, a PE ratio of -40.22 and a beta of 1.53. Natera has a 1 year low of $36.90 and a 1 year high of $133.54. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. The firm has a 50-day moving average price of $122.85 and a 200-day moving average price of $110.07.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The firm had revenue of $413.35 million for the quarter, compared to the consensus estimate of $343.00 million. During the same period in the previous year, the firm posted ($0.97) earnings per share. The firm’s revenue was up 58.1% on a year-over-year basis. Equities analysts anticipate that Natera will post -1.96 EPS for the current fiscal year.

Insider Transactions at Natera

In other Natera news, CFO Michael Burkes Brophy sold 499 shares of the stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $107.40, for a total value of $53,592.60. Following the completion of the sale, the chief financial officer now directly owns 77,418 shares of the company’s stock, valued at $8,314,693.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Natera news, CFO Michael Burkes Brophy sold 499 shares of the company’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $107.40, for a total value of $53,592.60. Following the completion of the transaction, the chief financial officer now owns 77,418 shares of the company’s stock, valued at $8,314,693.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Daniel Rabinowitz sold 1,057 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $102.77, for a total value of $108,627.89. Following the completion of the sale, the insider now owns 206,400 shares of the company’s stock, valued at $21,211,728. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 46,242 shares of company stock worth $5,426,901. Insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Natera

A number of hedge funds have recently made changes to their positions in the business. IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new stake in shares of Natera during the 3rd quarter valued at about $249,000. Creative Planning lifted its stake in Natera by 18.3% during the third quarter. Creative Planning now owns 5,833 shares of the medical research company’s stock worth $740,000 after purchasing an additional 904 shares during the period. Exchange Traded Concepts LLC lifted its stake in Natera by 30.5% during the third quarter. Exchange Traded Concepts LLC now owns 12,064 shares of the medical research company’s stock worth $1,532,000 after purchasing an additional 2,821 shares during the period. CWM LLC boosted its holdings in Natera by 119.5% during the third quarter. CWM LLC now owns 15,441 shares of the medical research company’s stock valued at $1,960,000 after purchasing an additional 8,406 shares in the last quarter. Finally, Connective Portfolio Management LLC grew its stake in shares of Natera by 40.6% in the 3rd quarter. Connective Portfolio Management LLC now owns 9,000 shares of the medical research company’s stock valued at $1,143,000 after purchasing an additional 2,600 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.